The new quinolones that are active against S. pneumoniae show considerable promise for the treatment of acute lower respiratory tract infections due to their enhanced activity against this and other respiratory pathogens. The results of resistance selection experiments suggest that it will be important to limit the use of earlier quinolones for respiratory infections - it is possible that these earlier agents will permit single mutations that will allow a second mutation which will then render the organism resistant.
|Number of pages
|Round Table Series - Royal Society of Medicine
|Published - 1 Jan 2002